Peripherally Acting μ-opioid Receptor Antagonists As Treatment Options for Constipation in Noncancer Pain Patients on Chronic Opioid Therapy

Overview

Journal Patient Prefer Adherence

Date 2017 Feb 9

PMID 28176913

Citations 16

Authors

Joseph V Pergolizzi Jr

Robert B Raffa

Marco Pappagallo

Charles Fleischer

Joseph Pergolizzi 3rd

Gianpietro Zampogna

Elizabeth Duval

Janan Hishmeh

Jo Ann LeQuang

Robert Taylor Jr

Affiliations

Soon will be listed here.

Abstract

Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting μ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting μ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.

Citing Articles

Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): A Post Hoc Analysis.

Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M J Clin Med. 2021; 10(18).

PMID: 34575301 PMC: 8472365. DOI: 10.3390/jcm10184193.

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.

Liao S, Slatkin N, Stambler N Drugs Aging. 2021; 38(6):503-511.

PMID: 33788162 PMC: 8211613. DOI: 10.1007/s40266-021-00850-w.

Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study.

Okamoto A, Ikemura K, Mizutani E, Iwamoto T, Okuda M J Pharm Health Care Sci. 2021; 7(1):3.

PMID: 33517900 PMC: 7849155. DOI: 10.1186/s40780-020-00187-3.

Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists.

Viscusi E, Viscusi A Reg Anesth Pain Med. 2020; 45(9):688-695.

PMID: 32723840 PMC: 7476292. DOI: 10.1136/rapm-2020-101403.

Synthesis, Radiosynthesis and Biological Evaluation of Buprenorphine-Derived Phenylazocarboxamides as Novel μ-Opioid Receptor Ligands.

Krull J, Fehler S, Hofmann L, Nebel N, Maschauer S, Prante O ChemMedChem. 2020; 15(13):1175-1186.

PMID: 32378310 PMC: 7383964. DOI: 10.1002/cmdc.202000180.

References

Weber H . Opioid-induced constipation in chronic noncancer pain. Curr Opin Endocrinol Diabetes Obes. 2015; 23(1):11-7. DOI: 10.1097/MED.0000000000000220. View

Gaertner J, Siemens W, Camilleri M, Davies A, Drossman D, Webster L . Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2014; 49(1):9-16. DOI: 10.1097/MCG.0000000000000246. View

Bruner H, Atayee R, Edmonds K, Buckholz G . Clinical utility of naloxegol in the treatment of opioid-induced constipation. J Pain Res. 2015; 8:289-94. PMC: 4472065. DOI: 10.2147/JPR.S61326. View

Trinkley K, Sill B, Porter K, Nahata M . Prescribing Patterns for Outpatient Treatment of Constipation, Irritable Bowel Syndrome-Related Constipation, and Opioid-Induced Constipation: A Retrospective Cross-Sectional Study. J Manag Care Spec Pharm. 2015; 21(11):1077-87. PMC: 10398309. DOI: 10.18553/jmcp.2015.21.11.1077. View

Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C . A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2008; 13(1):56-64. DOI: 10.1016/j.ejpain.2008.06.012. View

Pappagallo M . Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2002; 182(5A Suppl):11S-18S. DOI: 10.1016/s0002-9610(01)00782-6. View

Wald A . Constipation: Advances in Diagnosis and Treatment. JAMA. 2016; 315(2):185-91. DOI: 10.1001/jama.2015.16994. View

Poulsen J, Nilsson M, Brock C, Sandberg T, Krogh K, Drewes A . The Impact of Opioid Treatment on Regional Gastrointestinal Transit. J Neurogastroenterol Motil. 2016; 22(2):282-91. PMC: 4819867. DOI: 10.5056/jnm15175. View

Badke A, Rosielle D . Opioid Induced Constipation Part I: Established Management Strategies #294. J Palliat Med. 2015; 18(9):799-800. DOI: 10.1089/jpm.2015.0154. View

10.

Nelson A, Camilleri M . Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015; 8(4):206-20. PMC: 4480571. DOI: 10.1177/1756283X15578608. View

11.

Wald A . Constipation: pathophysiology and management. Curr Opin Gastroenterol. 2014; 31(1):45-9. DOI: 10.1097/MOG.0000000000000137. View

12.

. ▼Naloxegol for opioid-induced constipation. Drug Ther Bull. 2015; 53(12):138-40. DOI: 10.1136/dtb.2015.12.0369. View

13.

Webster L, Jansen J, Peppin J, Lasko B, Irving G, Morlion B . Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic.... Pain. 2008; 137(2):428-440. DOI: 10.1016/j.pain.2007.11.008. View

14.

Bagnol D, Mansour A, Akil H, Watson S . Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997; 81(2):579-91. DOI: 10.1016/s0306-4522(97)00227-3. View

15.

Holzer P . Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?. Curr Pharm Des. 2012; 18(37):6010-20. DOI: 10.2174/138161212803582388. View

16.

Nilsson M, Poulsen J, Brock C, Sandberg T, Gram M, Frokjaer J . Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI. Eur J Gastroenterol Hepatol. 2016; 28(5):514-24. DOI: 10.1097/MEG.0000000000000574. View

17.

Dunlop W, Uhl R, Khan I, Taylor A, Barton G . Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012; 15(3):564-75. DOI: 10.3111/13696998.2012.665279. View

18.

Koopmans-Klein G, Wagemans M, Wartenberg H, van Megen Y, Huygen F . The efficacy of standard laxative use for the prevention and treatment of opioid induced constipation during oxycodone use: a small Dutch observational pilot study. Expert Rev Gastroenterol Hepatol. 2015; 10(4):547-53. DOI: 10.1586/17474124.2016.1129275. View

19.

Rao S, Rattanakovit K, Patcharatrakul T . Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol. 2016; 13(5):295-305. DOI: 10.1038/nrgastro.2016.53. View

20.

Camilleri M, Bharucha A, Ueno R, Burton D, Thomforde G, Baxter K . Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G942-7. DOI: 10.1152/ajpgi.00264.2005. View